Olivares-Martínez, Elizabeth, Hernández-Ramírez, Diego Francisco, Núñez-Álvarez, Carlos Alberto et al. · International journal of molecular sciences · 2025 · DOI
Researchers tested a treatment called polymerized type I collagen (PTIC) in COVID-19 patients and found it may help reduce excessive inflammation by calming down immune cells called monocytes. The treatment appeared to improve breathing, reduce fatigue, chest pain, and cough in both the acute phase and long-term recovery from COVID-19. This finding could potentially be relevant for patients with long COVID or ME/CFS, which involve similar inflammatory problems.
ME/CFS shares underlying mechanisms with long COVID, including persistent STAT1-driven immune dysregulation and elevated pro-inflammatory cytokines. If PTIC's mechanism of action in reducing STAT1-mediated inflammation proves effective, it could offer a novel therapeutic approach for ME/CFS patients suffering from post-exertional malaise, fatigue, and dysautonomia. This study provides preliminary evidence that targeting specific immune receptors may help rebalance the inflammatory state characteristic of these conditions.
This study does not definitively prove that PTIC is effective for ME/CFS, as the patient cohort consisted only of COVID-19 outpatients, not ME/CFS patients. The correlational nature of the clinical findings does not establish causation—the observed symptom improvement could result from natural viral clearance or other concurrent treatments rather than PTIC alone. No placebo-controlled randomized trial is presented, and the abstract does not specify whether patients had documented post-exertional malaise or met formal ME/CFS diagnostic criteria.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →